The incidence of venous thromboembolism in chronic myeloid leukemia treatment based on the normalized million people file of National Health Insurance Research Database of Taiwan

CNU IR > Pharmacy and Science > 2016 > Item 310902800/31315

Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/31315

Title:	The incidence of venous thromboembolism in chronic myeloid leukemia treatment based on the normalized million people file of National Health Insurance Research Database of Taiwan
Authors:	CHIH-WEI SU TZ-CHYANG TANG
Contributors:	Department of Pharmacy, Chia Nan University of Pharmacy and Science
Date:	2016-05-10
Issue Date:	2018-05-21 10:34:29 (UTC+8)
Abstract:	Chronic myeloid leukemia (CML) is a myeloproliferative disorder of blood stem cells and amongst the most common hematological malignancies encountered in adults. Nowadays, many clinical trials data show the availability of the first and second-generation Tyrosine Kinase Inhibitor (TKI) (imatinib, nilotinib, and dasatinib) in the first and second line settings. Venous thromboembolism (VTE) is a life-threatening condition that occurs as a complication of CML. This study analyzed the data of the National Health Insurance Research Database (NHIRD) deposited from 2004 to 2013, which provided by the National Health Research Institutes in Taiwan. The major outcome reveals the relationship between disease treatment and severe adverse events, especially in VTE. 9506 appendectomy patients were eligible and 90 CML patients were routed out which received TKI drugs treatment. The 10-year cumulative risk for VTE was not significant in the CML group than in the control group (4.69% vs. 2.82%, P-value 0.1239). The rate of VTE among CML patients whom received TKI drugs was not significant, too. (2.22% vs. 2.82%, P-value 0.3502) 192 CML patients were diagnosed and 90 patients had received Tyrosine Kinase Inhibitor (TKI) drug for the treatment, while 9 patients encountered vein thromboembolism event. Only two patients have VTE event during Imatinib treat. This study was limited in which the population cannot cover all of CML patients. And we cannot link to the real clinical profile to analyze the adherence and clinical effect of patients. Following the analyzed results, the patients of elder or with more complication ones maybe have higher risk than normal population in VTE, and the incidence rate of VTE is not significant vs. control group. The incidence of VTE in CML patients should not associated with TKI drugs.
Relation:	2016 第十屆嘉南藥理大學藥理學院師生研究成果發表會，起迄日：2016/05/10-2016/05/13，地點：嘉南藥理大學國際會議中心一樓
Appears in Collections:	[Dept. of Pharmacy] Proceedings [Pharmacy and Science] 2016

Files in This Item:

File	Description	Size	Format
A15.pdf		468Kb	Adobe PDF	590	View/Open

Loading...